“Latest Stem Cells News”

Researchers at UTHealth have demonstrated in rats that transplanting genetically modified adult stem cells into an injured spinal cord can help restore the electrical pathways associated with movement. The results are published in today’s issue of the Journal of Neuroscience.

In spinal cord injury, demyelination, or the destruction of the myelin sheath in the central nervous system, occurs. The myelin sheath, produced by cells called oligodendrocytes, wraps around the axons of nerves and helps speed activity and insulate electrical conduction. Without it, the nerves cannot send messages to make muscles move.

The research team, led by Qilin Cao, M.D., principal investigator and associate professor of neurosurgery at UTHealth (The University of Texas Health Science Center at Houston), discovered that transplanted adult stem cells (oligodendrocyte precursor cells or OPC) from the spinal cord could become oligodendrocytes. The new cells helped restore electrical pathways of the spinal cord and therefore, function, in a process called remyelination.

Incoming search terms:

Look what we have here- another stem cell research trial for heart disease (congestive heart failure) and another heart patient has his life improved. This time, at the University of Louisville, the first heart failure patient treated with his own Adult Stem Cells has improved already, just 2 week after his stem cell treatment.

Adult Stem Cells Result in 30% Improvement

Michael Jones, a contractor in Louisville, was the first congestive heart failure patient to take part in this stem cell research trial. Here is more from the stem cell article:

His severe congestive heart failure was treated with the stem cell treatment. The procedure involved injecting his own cardiac stem cells into his damaged heart muscle. It was done on July 17. He shows already had 20-30% improvement of his heart function since the treatment.

Congestive Heart Failure Kills Millions Every Year- US Does Nothing

Heart failure is a leading cause of death in the United States, affecting some 6 million Americans a year. Half of the patients die within one year. Doctors have had little to offer patients with late-stage heart failure. With major muscle damage to the heart, patients have the option of a heart transplant or implantation of a mechanically assisted heart device.

What About The Millions Who Can’t Get Stem Cell Treatment?

This is good news right? Well yes and no. Yes, I am happy for Michael Jones as he is a lucky man to receive stem cell treatment using his own adult stem cells and unsurprisingly it has worked.

No, because what about the other millions of Americans who aren’t able to receive this stem cell treatment. The Fight Aging Website has a post on this:

It is only in the last couple of years that clinical trials have started for autologous stem cell therapies in the US. Or, to put it another way, for some time now unelected and largely unaccountable employees of the US government have forbidden US residents – on pain of criminal prosecution – from offering or making their own decisions about a medical technology commercially available elsewhere in the world. All the while, these bureaucrats impose vast costs on medical development concerns by insisting on largely pointless trials, continuing far past any reasonable trade-off between risk and reward, thereby greatly postponing the commerical introduction of these technologies in the US.

Do you have responsibility for, or even the ability to make your own medical choices? Not according to people in positions of power at the FDA. Regulation in medicine has largely become an exercise undertaken for its own sake, as is the end result of any centralization of power. No-one’s interests are being served save for those of the career bureaucrats in charge of forbidding new things. Everyone else gets to suffer due to the ball and chain shackled to medical progress, and due to being forbidden the basic, fundamental freedom to choose how to treat their own medical conditions.

Now ask yourself, why can’t anyone with heart disease and the necessary funds just up and do the research on the treatment and choose to try this within the borders of the US? Because a faceless bureaucrat has decided that it is forbidden, and that anyone who offers this treatment must be jailed. Welcome to the land of the free.

This is similar to what I argued here in this stem cell research post

Stem Cell Treatment Information

For treatment information, please fill out this stem cell treatment form- and one of the Repair Stem Cell Institute’s staff will provide you with more information – free.

For full information, write me at donmargolis@gmail.com and just put “Treatment”  in the subject box. Or, if you want to start the process to treat a loved one now, fill out this stem cell treatment form and one of the Repair Stem Cell Institute’s staff will provide you with all the help you need -free.

Incoming search terms:

Doctors with the University of Louisville and officials with Jewish Hospital Friday introduced the recipient of one of the world’s first adult cardiac stem cell infusion to treat congestive heart failure.

Michael Jones, 66, had his own cardiac stem cells injected directly into heart scar tissue, using a cardiac catheterization procedure, according to a news release.

Dr. Mark Slaughter, chief of the Division of Cardiothoracic Surgery at the University of Louisville and director of the Heart Transplant and Mechanical Assist Device Program at Jewish Hospital, performed coronary artery bypass surgery on Jones on March 23, according to the release.

Jones had congestive heart failure and permanent scarring of the heart resulting from multiple blocked arteries.
The cardiac stem cells injected into the scar tissue were removed from a portion of the upper chamber of Jones’ heart.

The tissue was sent to Harvard University and Brigham & Women’s Hospital in Boston, where the cardiac stem cells were grown.

The infusion was performed at Jewish Hospital by Dr. Sohail Ikram, a University of Louisville professor of medicine and director and chief of invasive and interventional cardiology at Jewish Hospital.

Leader of the study was Dr. Roberto Bolli, Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology and director of the University of Louisville’s Institute for Molecular Cardiology.
In the release, Bolli said the intent of the injection is to help the heart regenerate tissue and function.
The university and Jewish Hospital continue to enroll patients in the U.S. Food and Drug Administration-approved clinical trial.

from Business First

Incoming search terms: